The most commonly reported adverse effects in GLP-1 clinical trials include gastrointestinal symptoms such as nausea (occurring in 15-44% of patients depending on the specific agent and dose), vomiting, diarrhea, constipation, and abdominal pain
35 Following primary antibody incubation, the cells were washed and then incubated with an Alexa Fluor 488-conjugated anti-mouse secondary antibody (4408S, CST, MA, USA
Diarrhea or Constipation: Changes in bowel habits can occur as the digestive system adapts to the medication
Introducing Injectable NAD+ by Get Thin MD: The Ultimate Cellular Energy Booster for GLP-1 Users Our medical-grade NAD+ injection program delivers pure nicotinamide adenine dinucleotide directly to your system, providing immediate cellular energy and metabolic support: Targets fatigue at its source your cells' energy production centers Revitalizes metabolic function during caloric restriction Supports preservation of lean muscle mass Enhances mental clarity and cognitive function Works synergistically with your GLP-1 medication for optimal results Together, GLP-1 and NAD+ may have a synergistic effect
Hydration and energy effects are often felt the same day
